Publications by authors named "P Musette"
Article Synopsis
- The Ritux 3 trial showed that rituximab is effective and safe as a first-line treatment for pemphigus, although long-term follow-up data was previously lacking.!* -
- This 7-year follow-up study evaluated the long-term outcomes for patients treated with rituximab alongside prednisone versus those treated with prednisone alone, focusing on disease-free survival and relapse rates.!* -
- Results indicated that 93% of patients in the rituximab group achieved complete remission without corticosteroids, showing significantly higher disease-free survival and lower relapse rates compared to the prednisone-only group.!*
Mucous membrane pemphigoid (MMP) is a heterogeneous group of rare, chronic, subepithelial autoimmune blistering diseases (AIBDs) with predominant involvement of mucous membranes that can be sight-threatening and life-threatening. Rituximab (RTX) has demonstrated its efficacy in severe MMP refractory to conventional immunosuppressants in small series that differed in RTX scheme, concomitant therapies, and outcome definitions. In a meta-analysis involving 112 patients with MMP treated with RTX, complete remission (CR) was reported in 70.
View Article and Find Full Text PDFPemphigus represents a group of rare and severe autoimmune intra-epidermal blistering diseases affecting the skin and mucous membranes. These painful and debilitating diseases are driven by the production of autoantibodies that are mainly directed against the desmosomal adhesion proteins, desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1). The search to define underlying triggers for anti-Dsg-antibody production has revealed genetic, environmental, and possible vaccine-driven factors, but our knowledge of the processes underlying disease initiation and pathology remains incomplete.
View Article and Find Full Text PDF